GlobeNewswire Inc.··NaDesign Therapeutics to Unveil RESTORE-FA Trial Data for Friedreich's Ataxia Treatment
Design Therapeutics will present Phase 1/2 data for DT-216P2, its experimental Friedreich's ataxia treatment, on May 18, 2026.
DSGNgene therapyFriedreich's ataxia